Article Information
History
- July 6, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Arvind Chopra@,1,
- Preeti Chavan-Gautam2,
- Girish Tillu2,
- Manjit Saluja1,
- Swapnil Borse2,
- Sanjeev Sarmukaddam,
- Susmita Chaudhuri3,
- BCS Rao4,
- Babita Yadav4,
- Narayanam Srikanth4 and
- Bhushan Patwardhan2
- 1Centre for Rheumatic Diseases, Pune, India
- 2Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India
- 3Translational Health Science and Technology Institute, Faridabad, India
- 4Central Council for Research in Ayurvedic Sciences, New Delhi, India
- ↵@Corresponding Author:
Arvind Chopra, MD, Director and Chief Rheumatologist, Centre for Rheumatic Diseases, Pune, India 411001, Telephone: +91 20 26345624, (M) 9822039297, Email: arvindchopra60{at}hotmail.com
Posted July 06, 2021.
Randomized, double blind, placebo controlled, clinical trial to study co-administration of Ashwagandha on safety, immunogenicity, and protection with COVID-19 vaccine – A Study Protocol
